Johnson & Johnson JNJ

$261.44 +4.96 (1.93%)

Valuation

Market cap
618,090,624,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
23.80
Forward PE
22.88
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
5,727,200
Avg volume
6,565,684
Day's range
$254.99 – $261.61
Shares out
2,409,898,000
Stochastic %K
50%
Beta
0.21
Analysts
Strong Sell
Price target
$282.60

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

BioTechHealthX Oct 10, 5:54 AM
$JNJ Johnson & Johnson (NYSE: JNJ) heads into October 13 earnings with a higher annual outlook. Explore the growth and margin signals that could support its momentum. https://biotechhealthx.com/biotech-news/johnson-johnson-jnj-raised-the-bar-and-earnings-will-test-it/
0 replies
pairscopilot Oct 9, 10:13 PM
Nightly scan, Oct 9: nothing new triggered. Free look: $TJX / $ROST, gap ~5.9% vs normal, typical close ~5 days (estimate, not a schedule). Closest to firing: $TJX / $ROST (1.7% to go), $ABBV / $JNJ (2.0%). Model output, not advice.
0 replies
ryank3030 Oct 9, 8:36 PM
$EXPE closed out this morning at $270.13, +3.83% in 3 days 🎯 Bought Monday after the close at $260.17 and sold in the first few minutes of the open today. Nothing fancy: a pullback, a plan, and out when it hit. That's 3 for 3 on the swing book this week ($JNJ +2.5%, $MRK +2.5%, $EXPE +3.8%). Every trade, wins and losses, is logged publicly at https://bit.ly/4AXO1sx
0 replies
FinanceGreater Oct 9, 8:01 PM
$TSM Earnings season kicks off next week. $JPM $JNJ $ASML and more. Here are the key releases to watch October 12–16.
0 replies
topstockalerts Oct 9, 6:35 PM
Next week, earnings season gets into full swing with the banks set to report, as well as other notable names such as Johnson & Johnson and UnitedHealth . Those two are slated to report on Tuesday alongside others like Wells Fargo and Citigroup . While Michael Monaghan of Founder ETFs is constructive on equities through year-end given the “big growth” that’s anticipated to come out of companies, he still believes the conflict in the Middle East — and its impact on oil — could weigh on the market. That’s even after President Donald Trump said this week that the U.S. won’t attack Iran prior to the midterm elections early next month. $JNJ
0 replies
parcha Oct 9, 3:35 PM
https://www.cnbc.com/investingclub/2026/10/09/jim-cramers-top-10-things-to-watch-in-the-stock-market-friday.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension $LLY $JNJ Bank of America is all over the map on Club drug stocks. Price target cut on buy-rated Eli Lilly. PT raise on hold-rated Johnson & Johnson. The analysts tweaked their estimates for the industry ahead of earnings.
0 replies
Manny007 Oct 9, 12:37 PM
$JNJ $270-$280 next week
0 replies
focafoca99 Oct 9, 11:10 AM
$JNJ demonstrated robust 2-year Phase 3 data for ICOTYDE, with ~72% of patients achieving PASI 90 and ~44% reaching PASI 100. https://www.rapidticker.com/news/jnj-new-johnson-johnson-icotyde-icotrokinra-8c8e37
0 replies